This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
DNA/RNA heteroduplex oligonucleotide technology for regulating lymphocytes in vivo
Nature Communications Open Access 22 December 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
D’Souza AZX. Current uses and outcomes of hematopoietic cell transplantation (HCT): CIBMTR summary slides. http://www.cibmtr.org. 2016.
Choi SW, Reddy P. Current and emerging strategies for the prevention of graft-versus-host disease. Nat Rev Clin Oncol. 2014;11:536–47.
Choi J, Ziga ED, Ritchey J, Collins L, Prior JL, Cooper ML, et al. IFNgammaR signaling mediates alloreactive T-cell trafficking and GVHD. Blood. 2012;120:4093–103.
Wysocki CA, Panoskaltsis-Mortari A, Blazar BR, Serody JS. Leukocyte migration and graft-versus-host disease. Blood. 2005;105:4191–9.
Sackstein R. The lymphocyte homing receptors: gatekeepers of the multistep paradigm. Curr Opin Hematol. 2005;12:444–50.
Agace WW. Tissue-tropic effector T cells: generation and targeting opportunities. Nat Rev Immunol. 2006;6:682–92.
Petrovic A, Alpdogan O, Willis LM, Eng JM, Greenberg AS, Kappel BJ, et al. LPAM (alpha 4 beta 7 integrin) is an important homing integrin on alloreactive T cells in the development of intestinal graft-versus-host disease. Blood. 2004;103:1542–7.
Tanaka T, Ohtsuka Y, Yagita H, Shiratori Y, Omata M, Okumura K. Involvement of alpha 1 and alpha 4 integrins in gut mucosal injury of graft-versus-host disease. Int Immunol. 1995;7:1183–9.
Choi J, Cooper ML, Staser K, Ashami K, Vij KR, Wang B, et al. Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-versus-host disease. Leukemia. 2018;32:2483–94.
Leone DR, Giza K, Gill A, Dolinski BM, Yang W, Perper S, et al. An assessment of the mechanistic differences between two integrin alpha 4 beta 1 inhibitors, the monoclonal antibody TA-2 and the small molecule BIO5192, in rat experimental autoimmune encephalomyelitis. J Pharmacol Exp Ther. 2003;305:1150–62.
Cimo AM, Ahmed Z, McIntyre BW, Lewis DE, Ladbury JE. CD25 and CD69 induction by alpha4beta1 outside-in signalling requires TCR early signalling complex proteins. Biochemical J. 2013;454:109–21.
Du W, Leigh ND, Bian G, O’Neill RE, Mei L, Qiu J, et al. Granzyme B-mediated activation-induced death of CD4+ T cells inhibits murine acute graft-versus-host disease. J Immunol (Baltim, Md: 1950). 2015;195:4514–23.
Webb DL, Conrad PJ, Ma L, Blue M-L. Induction of mouse β integrin expression following transfection with human α4 chain. J Cell Biochem. 1996;61:127–38.
Mittelbrunn M, Molina A, Escribese MM, Yanez-Mo M, Escudero E, Ursa A, et al. VLA-4 integrin concentrates at the peripheral supramolecular activation complex of the immune synapse and drives T helper 1 responses. Proc Natl Acad Sci USA. 2004;101:11058–63.
Kekre N, Kim HT, Ho VT, Guo Y, Mahmood U, Belatreche W, et al. Phase II trial of natalizumab (Tysabri®) with corticosteroids as initial treatment of gastrointestinal acute graft versus host disease. Blood. 2017;130:3252.
Acknowledgements
JC is supported by Washington University SPORE-CDP (P50 CA171963-01), the Bryan Thomas Campbell Foundation, The Amy Strelzer Manasevit Research Program (Be The Match Foundation and National Marrow Donor Program), The Rays of Hope St. Baldrick’s Research Grant (St. Baldrick’s Foundation), and Alvin J. Siteman Cancer Center Siteman Investment Program (supported by the Foundation for Barnes-Jewish Hospital Cancer Frontier Fund, National Cancer Institute Cancer Center Support Grant, P30 CA091842, and Barnard Trust). JFD is supported by the National Cancer Institute (P50 CA94056-09, P50 CA171963-01, and R35 CA210084-01) and the Bryan Thomas Campbell Foundation. We thank Joel Eissenberg for critical reading of the manuscript.
Author information
Authors and Affiliations
Contributions
JC and JFD conceived and supervised the project. BA, MLC, PR, JC and JFD designed the study. BA, JC and JFD wrote the manuscript. BA, MLC, JR and JC performed the experiments. KV performed histopathological examination. BA and FG performed statistical analyses. All authors were involved in the interpretation of data and preparation of this manuscript.
Corresponding authors
Ethics declarations
Conflict of interest
JC received honorarium from Incyte Corporation, received research funding from Mallinckrodt Pharmaceuticals, and served as a consultant for Daewoong Pharmaceutical. JFD served on advisory boards for Incyte Corporation, CellWorks, Macrogenics, Amphivena, Arch, Rivervest, and Bioline and is a co-founder of Magenta Therapeutics and WUGen. Other authors declare that there is no conflict of interest.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Alahmari, B., Cooper, M.L., Vij, K. et al. Selective targeting of α4β1 integrin attenuates murine graft versus host disease. Leukemia 34, 3100–3104 (2020). https://doi.org/10.1038/s41375-020-0786-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41375-020-0786-0